BRIEF-Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701

Reuters04-30

April 29 (Reuters) - Terns Pharmaceuticals Inc :

* TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1 PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701 IN ADULT HEALTHY VOLUNTEERS AND HIGHLIGHTS POTENTIAL FOR COMPETITIVE DIFFERENTIATION

* TERNS PHARMACEUTICALS INC - INTERIM DATA FROM PHASE 1 CARDINAL TRIAL INITIAL COHORTS ANTICIPATED IN SECOND HALF OF 2024

* TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND FASTED DOSING

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431402178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-30 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431402178","market":"us","top_or_hot":-1,"title":"BRIEF-Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701","media":"Reuters","content":"<html><body><p>April 29 (Reuters) - Terns Pharmaceuticals Inc   :</p><p>   * TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1 PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701 IN ADULT HEALTHY VOLUNTEERS AND HIGHLIGHTS POTENTIAL FOR COMPETITIVE DIFFERENTIATION</p><p>   * TERNS PHARMACEUTICALS INC -  INTERIM DATA FROM PHASE 1 CARDINAL TRIAL INITIAL COHORTS ANTICIPATED IN SECOND HALF OF 2024</p><p>   * TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND FASTED DOSING</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 04:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 29 (Reuters) - Terns Pharmaceuticals Inc   :   * TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1 PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701 IN ADULT HEALTHY ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2431402178","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431402178","pubTimestamp":1714422158,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 29  - Terns Pharmaceuticals Inc   :   * TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1 PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701 IN ADULT HEALTHY VOLUNTEERS AND HIGHLIGHTS POTENTIAL FOR COMPETITIVE DIFFERENTIATION   * TERNS PHARMACEUTICALS INC -  INTERIM DATA FROM PHASE 1 CARDINAL TRIAL INITIAL COHORTS ANTICIPATED IN SECOND HALF OF 2024   * TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND FASTED DOSINGSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"简介——Terns Pharmaceuticals公布正在进行的变构Bcr-Abl抑制剂Tern-701的1期药代动力学研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":1},"content_text":"April 29 (Reuters) - Terns Pharmaceuticals Inc   :   * TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1 PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701 IN ADULT HEALTHY VOLUNTEERS AND HIGHLIGHTS POTENTIAL FOR COMPETITIVE DIFFERENTIATION   * TERNS PHARMACEUTICALS INC -  INTERIM DATA FROM PHASE 1 CARDINAL TRIAL INITIAL COHORTS ANTICIPATED IN SECOND HALF OF 2024   * TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND FASTED DOSINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431402178"}